1. Home
  2. IDYA vs WLYB Comparison

IDYA vs WLYB Comparison

Compare IDYA & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • WLYB
  • Stock Information
  • Founded
  • IDYA 2015
  • WLYB 1807
  • Country
  • IDYA United States
  • WLYB United States
  • Employees
  • IDYA N/A
  • WLYB N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • WLYB Books
  • Sector
  • IDYA Health Care
  • WLYB Consumer Discretionary
  • Exchange
  • IDYA Nasdaq
  • WLYB Nasdaq
  • Market Cap
  • IDYA 2.6B
  • WLYB 2.7B
  • IPO Year
  • IDYA 2019
  • WLYB N/A
  • Fundamental
  • Price
  • IDYA $26.64
  • WLYB $51.93
  • Analyst Decision
  • IDYA Strong Buy
  • WLYB
  • Analyst Count
  • IDYA 12
  • WLYB 0
  • Target Price
  • IDYA $53.08
  • WLYB N/A
  • AVG Volume (30 Days)
  • IDYA 750.9K
  • WLYB 193.0
  • Earning Date
  • IDYA 11-04-2024
  • WLYB 12-04-2024
  • Dividend Yield
  • IDYA N/A
  • WLYB 2.68%
  • EPS Growth
  • IDYA N/A
  • WLYB N/A
  • EPS
  • IDYA N/A
  • WLYB N/A
  • Revenue
  • IDYA $3,922,000.00
  • WLYB $1,825,783,000.00
  • Revenue This Year
  • IDYA N/A
  • WLYB N/A
  • Revenue Next Year
  • IDYA $158.10
  • WLYB $1.12
  • P/E Ratio
  • IDYA N/A
  • WLYB N/A
  • Revenue Growth
  • IDYA N/A
  • WLYB N/A
  • 52 Week Low
  • IDYA $26.41
  • WLYB $28.35
  • 52 Week High
  • IDYA $47.74
  • WLYB $52.58
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 33.96
  • WLYB 69.63
  • Support Level
  • IDYA $27.52
  • WLYB $49.30
  • Resistance Level
  • IDYA $32.67
  • WLYB $52.29
  • Average True Range (ATR)
  • IDYA 1.44
  • WLYB 0.08
  • MACD
  • IDYA -0.04
  • WLYB 0.16
  • Stochastic Oscillator
  • IDYA 3.75
  • WLYB 88.77

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.

Share on Social Networks: